BCMA/TNFRSF17 Protein, Human (His & hFc), PE conjugated

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

Pack Size	Availability	Price/USD
25 μg	In stock	$ 247.00
50 μg	5 days	$ 384.00
100 μg	5 days	$ 597.00
200 μg	5 days	$ 968.00

Pack Size

Availability

Price/USD

Quantity

25 μg

In stock

$ 247.00

50 μg

5 days

$ 384.00

100 μg

5 days

$ 597.00

200 μg

5 days

$ 968.00

Biological Information

Tested by Flow cytometric analysis of anti-BCMA CAR expression.

Description

Species	Human
Expression System	HEK293
Tag	His,Fc
Accession Number	NP_001183.2
Synonyms	BCMA, TNFRSF13A, tumor necrosis factor receptor superfamily member 17, BCM, CD269
Construction	Recombinant human BCMA/TNFRSF17 (NP_001183.2, extracellular domain, Met 1-Ala 54) are conjugated with PE under optimum conditions, the unreacted PE was removed.

Formulation	Aqueous solution containing 0. 5% BSA and 0. 03%Proclin 300
Stability & Storage	This reagent is stable for 6 months from date of receipt when stored at 2℃ - 8℃. Protected from prolonged exposure to light. Do not freeze !
Shipping	Shipping at ambient temperature.
Research Background	Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.